Larissa A Meyer1, Alpa M Nick2, Qiuling Shi3, Xin Shelley Wang3, Loretta Williams3, Tremaine Brock2, Maria D Iniesta2, Kelly Rangel2, Karen H Lu2, Pedro T Ramirez2. 1. The University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology and Reproductive Medicine, USA(1). Electronic address: lmeyer@mdanderson.org. 2. The University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology and Reproductive Medicine, USA(1). 3. The University of Texas MD Anderson Cancer Center, Department of Symptom Research, USA.
Abstract
OBJECTIVE: With the growing focus on patient-centered care, patient reported outcomes (PROs) are becoming an important component to clinical trials and quality metrics. The objective of this study was to pilot the collection of patient reported symptom burden in women undergoing surgery in a gynecologic oncology practice. METHODS: Perioperative patient reported symptom burden was measured for women undergoing laparotomy on the gynecologic oncology service at the University of Texas MD Anderson Cancer Center. Symptoms were assessed using the M.D. Anderson Symptom Inventory (MDASI-OC), a 27 item tool validated for use in patients with ovarian cancer. The MDASI-OC was administered as a preoperative baseline, daily while admitted to the hospital after surgery, twice a week on the first week after discharge and then weekly until 8 weeks postoperatively. RESULTS: 29 patients were evaluable. Seventy-five percent of patients had a diagnosis of ovarian cancer. Of those patients, half underwent a primary debulking surgery and the other half had neoadjuvant chemotherapy prior to interval cytoreductive surgery. In the postoperative inpatient setting, the five symptoms with the highest overall burden were fatigue, pain, abdominal pain, dry mouth and drowsiness. Longitudinal change of the top 5 symptoms during hospitalization did not show any significant difference between those who had neoadjuvant chemotherapy and those who did not. CONCLUSION: The collection of longitudinal PROs to assess symptom burden is feasible in patients undergoing gynecologic oncology surgery. Patient reported outcomes are a crucial component of patient-centered research and the longitudinal collection and analysis of symptom burden can allow for more meaningful comparisons of surgical technique and perioperative care.
OBJECTIVE: With the growing focus on patient-centered care, patient reported outcomes (PROs) are becoming an important component to clinical trials and quality metrics. The objective of this study was to pilot the collection of patient reported symptom burden in women undergoing surgery in a gynecologic oncology practice. METHODS: Perioperative patient reported symptom burden was measured for women undergoing laparotomy on the gynecologic oncology service at the University of Texas MD Anderson Cancer Center. Symptoms were assessed using the M.D. Anderson Symptom Inventory (MDASI-OC), a 27 item tool validated for use in patients with ovarian cancer. The MDASI-OC was administered as a preoperative baseline, daily while admitted to the hospital after surgery, twice a week on the first week after discharge and then weekly until 8 weeks postoperatively. RESULTS: 29 patients were evaluable. Seventy-five percent of patients had a diagnosis of ovarian cancer. Of those patients, half underwent a primary debulking surgery and the other half had neoadjuvant chemotherapy prior to interval cytoreductive surgery. In the postoperative inpatient setting, the five symptoms with the highest overall burden were fatigue, pain, abdominal pain, dry mouth and drowsiness. Longitudinal change of the top 5 symptoms during hospitalization did not show any significant difference between those who had neoadjuvant chemotherapy and those who did not. CONCLUSION: The collection of longitudinal PROs to assess symptom burden is feasible in patients undergoing gynecologic oncology surgery. Patient reported outcomes are a crucial component of patient-centered research and the longitudinal collection and analysis of symptom burden can allow for more meaningful comparisons of surgical technique and perioperative care.
Authors: Elfriede Greimel; Gunnar B Kristensen; Maria E L van der Burg; Pluvio Coronado; Gordon Rustin; Angel Sanchez del Rio; Nicholas S Reed; Randi R Nordal; Corneel Coens; Ignace Vergote Journal: Gynecol Oncol Date: 2013-08-27 Impact factor: 5.482
Authors: Ethan Basch; Bryce B Reeve; Sandra A Mitchell; Steven B Clauser; Lori M Minasian; Amylou C Dueck; Tito R Mendoza; Jennifer Hay; Thomas M Atkinson; Amy P Abernethy; Deborah W Bruner; Charles S Cleeland; Jeff A Sloan; Ram Chilukuri; Paul Baumgartner; Andrea Denicoff; Diane St Germain; Ann M O'Mara; Alice Chen; Joseph Kelaghan; Antonia V Bennett; Laura Sit; Lauren Rogak; Allison Barz; Diane B Paul; Deborah Schrag Journal: J Natl Cancer Inst Date: 2014-09-29 Impact factor: 13.506
Authors: Desiree Jones; Elisabeth G Vichaya; Charles S Cleeland; Lorenzo Cohen; Seema M Thekdi; Xin Shelley Wang; Michael J Fisch Journal: J Oncol Pract Date: 2013-11-26 Impact factor: 3.840
Authors: Loretta A Williams; Sonika Agarwal; Diane C Bodurka; Angele K Saleeba; Charlotte C Sun; Charles S Cleeland Journal: J Pain Symptom Manage Date: 2013-04-22 Impact factor: 3.612
Authors: Ethan Basch; Amy P Abernethy; C Daniel Mullins; Bryce B Reeve; Mary Lou Smith; Stephen Joel Coons; Jeff Sloan; Keith Wenzel; Cynthia Chauhan; Wayland Eppard; Elizabeth S Frank; Joseph Lipscomb; Stephen A Raymond; Merianne Spencer; Sean Tunis Journal: J Clin Oncol Date: 2012-10-15 Impact factor: 44.544
Authors: Mary H Sailors; Diane C Bodurka; Ibrahima Gning; Lois M Ramondetta; Loretta A Williams; Tito R Mendoza; Sonika Agarwal; Charlotte C Sun; Charles S Cleeland Journal: Gynecol Oncol Date: 2013-05-15 Impact factor: 5.482
Authors: K M Doll; A C Snavely; A Kalinowski; D E Irwin; J T Bensen; V Bae-Jump; J F Boggess; J T Soper; W R Brewster; P A Gehrig Journal: Gynecol Oncol Date: 2014-04-12 Impact factor: 5.482
Authors: Bryce B Reeve; Sandra A Mitchell; Amylou C Dueck; Ethan Basch; David Cella; Carolyn Miller Reilly; Lori M Minasian; Andrea M Denicoff; Ann M O'Mara; Michael J Fisch; Cynthia Chauhan; Neil K Aaronson; Corneel Coens; Deborah Watkins Bruner Journal: J Natl Cancer Inst Date: 2014-07-08 Impact factor: 13.506
Authors: Laura Ashley; Helen Jones; James Thomas; Alex Newsham; Amy Downing; Eva Morris; Julia Brown; Galina Velikova; David Forman; Penny Wright Journal: J Med Internet Res Date: 2013-10-25 Impact factor: 5.428
Authors: Renee A Cowan; Rudy S Suidan; Vaagn Andikyan; Youssef A Rezk; M Heather Einstein; Kaity Chang; Jeanne Carter; Oliver Zivanovic; Elizabeth J Jewell; Nadeem R Abu-Rustum; Ethan Basch; Dennis S Chi Journal: Gynecol Oncol Date: 2016-09-13 Impact factor: 5.482
Authors: Bojoura Schouten; Bert Avau; Geertruida Trudy E Bekkering; Patrick Vankrunkelsven; Jeroen Mebis; Johan Hellings; Ann Van Hecke Journal: Cochrane Database Syst Rev Date: 2019-03-26
Authors: Laleh G Melstrom; Andrei S Rodin; Lorenzo A Rossi; Paul Fu; Yuman Fong; Virginia Sun Journal: J Surg Oncol Date: 2020-09-24 Impact factor: 3.454
Authors: Bojoura Schouten; Johan Hellings; Elke Van Hoof; Patrick Vankrunkelsven; Paul Bulens; Frank Buntinx; Jeroen Mebis; Dominique Vandijck; Ward Schrooten Journal: BMC Cancer Date: 2016-08-30 Impact factor: 4.430